phase ii results of olaparib and abiraterone for mcrpc
Published 6 years ago • 50 plays • Length 4:21Download video MP4
Download video MP3
Similar videos
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
2:19
phase iii results of olaparib for brca breast cancer
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
2:10
dr. gulley discusses a phase ii study of olaparib and durvalumab in mcrpc
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
5:52
talapro-1: phase ii study of talazoparib in patients with dna damage repair alterations and mcrpc
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
2:04
results of a phase ii study of lhrh therapy in high-risk prostate cancer
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc
-
5:00
phase iii results of prospect study for metastatic, castration-resistant prostate cancer
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
18:54
asco 2018: latest developments in non-metastatic & metastatic castration-resistant prostate cancer
-
5:36
propel trial